Liraglutide

Description

Liraglutide is a recombinant DNA produced polypeptide analog of human glucagon-like peptide-1 (GLP-1). Unlike the natural GLP-1 hormone, the effects of Liraglutide last up to 24 hours. There have been no published reports of hepatotoxicity attributed to Liraglutide therapy.

Clinical Research Application

Type 2 diabetics

Liraglutide is used to treat type 2 diabetes in combination with diet and exercise, either alone or in combination with other hypoglycemic agents. Liraglutide's hypoglycemic mechanism is primarily based on stimulating pancreatic islet B-cell proliferation, increasing insulin secretion and decreasing hepatic glucose production, resulting in long-term stabilization of blood glucose.

Obesity

Liraglutide reduces appetite by activating GLP-1 receptors in the brain, regulates intestinal flora and increases satiety by delaying gastric emptying, resulting in weight loss.

Other potential applications

Liraglutide may also have varying degrees of adjunctive therapeutic effects on non-diabetic neuromodulation, psychiatric disorders and cardiovascular protection.

List of Commercial Drugs with Liraglutide as Active Ingredient